Neurobiological Tech (NTII) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII)

NTII 0.0001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (354)	9/19/1998 9:58:00 AM
From: NeuroInvestment	Read Replies (1) of 1494

This brief note regarding memantine/Alzheimer's findings was published in the September issue of NeuroInvestment; I am posting it here at the request of Dr.DeCastro: Neurobiological Technologies's memantine partner Merz released for the first time Phase II data on memantine in Alzheimer's. In a 166 pt Swedish study, patients receiving memantine showed significantly (p=.001) better rates of improvement than those receiving placebo on a measure of functional change, and significant results on another measure of functional capacity. No objective measures of cognitive/memory functioning were utilized, which means that the study rested upon clinically relevant but 'softer' observer ratings. No significant side effects were noted, of particular importance given the difficulties other NMDA-antagonists have encountered with adverse CNS effects. NeuroInvestment (www.neuroinv.com)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next